

Press Release

India Formulations business up 23%

Net Profit Rs 169 crores

Vadodara, November 10th, 2021

Alembic Pharmaceuticals Limited reported its consolidated financial results for the quarter ending 30th September 2021.

Financial Highlights

- Net Sales for the quarter at Rs 1292 crores.
- Net Profit for the quarter at Rs 169 crores.
- Net sales for H-1 FY21 at Rs 2618 crores.
- Net profit for H-1 FY21 at Rs 334 crores.

Mr. Shaunak Amin, Managing Director, Alembic Pharmaceuticals Limited said "India Branded Formulation business has posted a strong growth rate for the second consecutive quarter. This is attributed to the consistent efforts to redefine our business strategy and customer relationships, leading to a strong operational performance, along with a market outperforming growth across all our key product segments and therapy areas."

Operational Highlights

International Business


- US Generics at Rs 348 crores in the quarter and at Rs 716 Crores for H-1.
- Ex-US International Formulations at Rs 197 Crores in the quarter and at Rs 394 Crores for H-1.
- 5 ANDA approvals received during the quarter; 150 Cumulative ANDA approvals.
- 3 ANDA filings during the quarter; Cumulative ANDA filings at 214.

India Formulations Business

- India Formulations Business at Rs 509 crores in the quarter and at Rs 989 crores in the H-1.
- Acute & specialty segment grew faster than represented pharma market.

API Business

- API business at Rs 239 crores in the quarter and at Rs 519 crores for H-1.
- 3 DMF were filed in the quarter.



ALEMBIC PHARMACEUTICALS LIMITED

REGD. OFFICE : ALEMBIC ROAD, VADODARA - 390 003. • TEL : (0265) 2280550, 2280880 • FAX : (0265) 2281229
website : www.alembicpharmaceuticals.com • E-mail : alembic@alembic.co.in • CIN : L24230GJ2010PLC061123

Summary of Total Revenue is as under:

(Rs in Crores)

Particulars	Q2 FY22	Q2 FY21	% Change	H-1 FY22	H-1 FY21	% Change
Formulation						
USA	348	582	(40%)	716	1177	(39%)
Ex- US	197	197	0%	394	373	6%
India	509	415	23%	989	721	37%
API	239	263	(9%)	519	528	(2%)
Total	1292	1457	(11%)	2618	2798	(6%)

Summary of Profit is as under:

(Rs in Crores)

Particulars	Q2 FY22	Q2 FY21	% Change	H1 FY22	H1 FY21	% Change
EBITDA Pre R&D	420	628	(33%)	827	1177	(30%)
<i>EBITDA Pre R&D %</i>	33%	43%		32%	42%	
EBITDA Post R&D	268	455	(41%)	522	871	(40%)
<i>EBITDA Post R&D %</i>	21%	31%		20%	31%	
Profit Before Tax	209	406	(49%)	408	775	(47%)
Net Profit after Tax	169	333	(49%)	334	635	(47%)



ALEMBIC PHARMACEUTICALS LIMITED

REGD. OFFICE : ALEMBIC ROAD, VADODARA - 390 003. • TEL : (0265) 2280550, 2280880 • FAX : (0265) 2281229
 website : www.alembicpharmaceuticals.com • E-mail : alembic@alembic.co.in • CIN : L24230GJ2010PLC061123

About Alembic Pharmaceuticals Limited

Alembic Pharmaceuticals Limited, a vertically integrated research and development pharmaceutical company, has been at the forefront of healthcare since 1907. Headquartered in India, Alembic is a publicly listed company that manufactures and markets generic pharmaceutical products all over the world. Alembic's state of the art research and manufacturing facilities are approved by regulatory authorities of many developed countries including the US FDA. Alembic is one of the leaders in branded generics in India. Alembic's brands, marketed through a marketing team of over 5000 are well recognized by doctors and patients.

Information about the company can be found at www.alembicpharmaceuticals.com;
(reuters:ALEM.NS) (bloomberg:ALPM) (nse:APLLTD) (bse:533573)

For more information contact:

Ajay Kumar Desai Phone: +91 22 – 306 11681 Email: ajay.desai@alembic.co.in	Mitanshu Shah Phone: +91 265 – 3007630 Email: mitanshu.shah@alembic.co.in
-----------------------------------------------------------------------------------------------------------------------------------------------	-------------------------------------------------------------------------------------------------------------------------------------------------



ALEMBIC PHARMACEUTICALS LIMITED

REGD. OFFICE : ALEMBIC ROAD, VADODARA - 390 003. • TEL : (0265) 2280550, 2280880 • FAX : (0265) 2281229
website : www.alembicpharmaceuticals.com • E-mail : alembic@alembic.co.in • CIN : L24230GJ2010PLC061123